New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:27 EDTAGRXAgile Therapeutics initiated with a Buy at Janney Capital
Target $18.
News For AGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:00 EDTAGRXAgile Therapeutics announces dosing of first patients in Twirla Phase 3 study
Agile Therapeutics announced that the first patients have been dosed in its SECURE study. The SECURE study is a single-arm, open-label, multicenter Phase 3 trial that will assess the efficacy, safety and tolerability of Agile's investigational once-weekly transdermal contraceptive patch, Twirla. Approximately 2,100 female subjects are expected to be enrolled at up to 70 sites in the United States. Patients meeting all eligibility criteria will use the patch for up to one year. The study will assess the effectiveness of the patch in preventing pregnancy using the Pearl Index as the primary contraceptive efficacy measure. Safety and tolerability will also be evaluated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use